Email Updates

You are here

Home

30 JULY 2021 VOLUME 23 ISSUE 30

Media Coverage

  • Opinion: I Fled Nigeria for My Safety. But Many Other LGBT+ Activists Remain Under Threat in My Country

    I come from Nigeria, one of the 68 countries that continue to criminalize same-sex relations. I had to flee for my life and seek asylum in the US. I was lucky; most people cannot flee. But I was also unlucky because we should not have to flee. In order to protect LGBT+ people in the most hostile places, the possibility to seek asylum is crucial and has to be protected. But what is more, we have to support activists on the ground fighting for change and for safety, so that LGBT+ people can live as their true selves everywhere, without having to flee for safety.

    July 29, 2021
    General
    Thomson Reuters Foundation

  • Insurers Will Now Have to Fully Cover PrEP and Its Visits and Labs—but Advocates Want the CDC to Do More

    Only three months after HIV drugmaker giant Gilead Sciences announced that it would dramatically cut back payments that countless clinics nationwide rely on to cover visits and labs related to their patients’ care on the HIV-prevention regimen PrEP (pre-exposure prophylaxis), along comes another new plot point in the ongoing saga of US PrEP access.

    July 29, 2021
    PrEP
    The Body

  • Ambitious Plan To Stem HIV/AIDS Epidemic Meets None Of Its Goals

    In 2015, global groups set ambitious goals to stem the HIV/AIDS epidemic. They aimed to bring down the number of new cases, particularly among children, teens and young women, by 2020 – and to bring up the number of people on HIV treatment.

    July 29, 2021
    General
    NPR Goats and Soda

  • COVID-19 Challenges Raise Concerns Over Future Funding for HIV

    A new report from KFF (Kaiser Family Foundation) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) finds that donor government disbursements to combat HIV in low-and middle-income countries increased by $377 million in 2020, reaching $8.2 billion in 2020 compared to US$7.8 billion in 2019. Donor government funding supports HIV care and treatment, prevention, and other services in low- and middle-income countries.

    July 29, 2021
    General
    The Guardian

  • Biden Administration Orders Insurers To Cover Costs For HIV Prevention Treatment PrEP

    NPR's Steve Inskeep talks to James Krellenstein of the advocacy group PrEP4All, about the White House ordering insurers to cover all costs of a treatment that prevents HIV infection.

    July 29, 2021
    PrEP
    NPR

  • Long-Acting HIV-Prevention Drugs May Be Key to Beating the Epidemic in the US

    Almost a decade after the daily HIV-prevention pill hit the market, long-acting forms of this public health tool, including a drug-infused implant meant to last a year, have shown promise in clinical trials.

    July 28, 2021
    PrEP
    NBC News

  • HIV Vaccines and Immunotherapies “Would Be Further Along” if They Had the Resources of COVID-19, Says Leading Antibody Researcher

    “Money does solve problems, there’s no question!” This was the answer by Professor Lynn Morris of the University of Witwatersrand in South Africa to an audience member at the 11th International AIDS Society Conference on HIV Science (IAS 2021) last week, in a plenary dealing with HIV vaccines and immunotherapy with antibodies.

    July 28, 2021
    HIV Vaccine
    aidsmap

  • Better Late Than Never: Indonesia Readies HIV Prevention Drug PrEP

    Thirty-three-year-old Sandy was diagnosed with HIV on Aug. 26, 2019. Married with one daughter, who turns 4 years old this year, Sandy began receiving antiretroviral treatment (ART) three days after the diagnosis to suppress the virus in his body. For double protection, he wears condoms whenever he has sex with his wife.

    July 28, 2021
    PrEP
    The Jakarta Post

  • Young Women and Pregnant Women Can Effectively Use Vaginal Rings and Oral PrEP for HIV Prevention

    Adolescent girls and young women can consistently use the dapivirine vaginal ring and daily pills for HIV pre-exposure prophylaxis (PrEP) when they receive adherence support, according to a study presented last week at the 11th International AIDS Society Conference on HIV Science (IAS 2021). Encouragingly, adherence to both methods was higher in this study than rates seen in prior trials. Another study found that both the ring and oral PrEP were safe for pregnant women, which to date has been an understudied population for HIV prevention.

    July 28, 2021
    Microbicides, PrEP
    aidsmap

  • Pricing Agreement Brings HIV Drug Darunavir Within Reach of LMICs

    Indian pharmaceutical company Hetero Labs Ltd will make a generic version of HIV drug darunavir boosted with ritonavir, known as DRV/r, at the price of $210 per patient per year for 90 countries, the majority of which are low or middle income.

    July 27, 2021
    Treatment
    Devex

  • In-Depth: SA Pharmacists Will Soon Be Able To Prescribe HIV Treatment

    South Africa is on the brink of allowing pharmacists holding the required permits to prescribe and initiate HIV medicines without people first having to get scripts from doctors or nurses.

    July 27, 2021
    Treatment
    Spotlight

  • A Turning Point for Children: Creating an AIDS-Free Generation

    Forty years after the first AIDS cases were reported, the harsh reality is that deep inequalities continue to exist in the global response to HIV and AIDS, with gaps in rights and services preventing real progress.

    July 25, 2021
    General
    STAT

  • The Military’s HIV Policies Are Discriminatory — And Decades Behind the Times

    Nicholas Harrison joined the Army in 2000, when he was 23; after a few years, he left active duty to go to college, hoping to become an Army lawyer. He earned his BA, and then a law degree, while a reservist in the Oklahoma National Guard. In 2013, after tours with the Army in Afghanistan and Kuwait, he was offered his dream job: a position in the Judge Advocate General Corps for the DC National Guard.

    July 22, 2021
    General
    Washington Post

  • Finally – Better Antiretroviral Drugs for Children with HIV

    Children living with HIV in six African countries will soon get access to the antiretroviral (ARV) drug, dolutegravir (DTG), which is more effective, easier to take and has fewer side effects than many other ARVs.

    July 20, 2021
    Treatment
    Health Policy Watch

Published Research

Announcements